Overview A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors Status: Terminated Trial end date: 2009-11-01 Target enrollment: Participant gender: Summary This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors. Phase: Phase 1 Details Lead Sponsor: Cyclacel Pharmaceuticals, Inc.